ISSN: 2689-7822
Authors:
The article presents the first case of disseminated mucormycosis caused by Lichtheimia ornata, as well as an overview of our register data and analysis of publications on mucormycosis caused by Lichtheimia spp. Main underlying conditions in our patients with Lichtheimia mucormycosis were hematological malignancies (83%). Main risk factor was prolonged (median -47 days) severe neutropenia (72%), and steroids were used relatively rarely (55%). Lichtheimia mucormycosis was severe disease with ≥ 2 organs involvement in 66% patients. Combination therapy (lipid forms amphotericin B with echinocandins) and surgical treatment were often used for the treatment of Lichtheimia mucormycosis. The 12-weeks overall survival rate of patients with Lichtheimia mucormycosis was 44%.
Keywords: Lichtheimia spp.; Lichtheimia ornate; Mucormycosis; Rhinocerebral mucormycosis; zygomycosis
Chat with us on WhatsApp